Projects and grants

Last and current projects:

Transcription factor MITF – key regulator of proliferation and survival of melanoma cells a molecular target of antitumor therapy. (IGA MH CR no. NT/11229-3, 2010-2012), (J.Vachtenheim - principal investigator)

Hedgehog-GLI signalling: an indicator of the tumor biological behavior in melanoma, lung cancer and some other tumors and its blocking as an antitumor therapy (IGA MH CR no. NT/14005, 2013-2015), (J.Vachtenheim - principal investigator)

Transcription factor MITF as a possible target of the antitumor therapy of melanoma – importance of MITF level for tumor phenotype an therapy. (GAUK no. 172214, 2014-1016), (K. Vlčková - principal investigator, J.Vachtenheim - supervisor)

Combination of three low-molecular weight inhibitors of signaling pathways in one drug as an efficient and complete eradication of malignant melanoma cells (GAMA4-TAČR no. TG01010108, 2017-2019), (J.Vachtenheim - principal investigator)

Progres Q25. Institutional project of the Charles University Prague (2017-2021), (J.Vachtenheim - principal investigator)

Financial support from League against Cancer, Prague (in cooperation with the University Hospital Motol), 2019

Financial support from League against Cancer, Prague (in cooperation with the University Hospital Motol), 2022

Financial support from League against Cancer, Prague (in cooperation with the University Hospital Motol), 2023

Financial support from League against Cancer, Prague (in cooperation with the University Hospital Motol), 2024

Financial support from League against Cancer, Prague (in cooperation with the University Hospital Motol), 2025

Cooperatio. Institutional project of the Charles University Prague, (Prof. T. Zima - principal investigator), 2021-up to now

(Support from cooperating laboratories.)